Research programme: malaria vaccine - GenVec/Laboratory of Malaria Immunology and Vaccinology
Latest Information Update: 28 May 2019
At a glance
- Originator GenVec; Laboratory of Malaria Immunology and Vaccinology
- Class Antimalarials; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Malaria in USA (Parenteral, Injection)
- 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
- 21 Apr 2015 GenVec and Laboratory of Malaria Immunology and Vaccinology (National Institute of Allergy and Infectious Diseases) agree to co-develop vaccines in USA for Malaria